Bill Cassidy actually said...

The House and the Senate have been interested in consolidating duplicative programs.

What percent of your facilities would have access to expertise such as this?

There is no evidence that for non-cancer pain longer than 90 days, that risk appears to outweigh benefit.

Implicit in what you were saying is that different divisions of the FDA have different rates of approval.